PORTLAND, Ore.--(BUSINESS WIRE)--Oct. 3, 2005--AVI BioPharma, Inc. (Nasdaq:AVII), today announced that the U.S. Senate Committee on Appropriations has approved $22 million for AVI’s research and development programs as part of the FY2006 defense spending bill. The spending bill must now be approved by the full Senate, and the total amount awarded to AVI is subject to change.
